Clinical Trials Browser

Interventional × Ovarian Neoplasms × IT-101 × Clear all

NCT02389985 2020-05-28

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1/2 Terminated

Ovarian Neoplasms

NCT01652079 2018-07-02

CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

Phase 2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms